Vivaldi develops high-growth influenza vaccine strains

Vivaldi’s technology leadership and expertise in influenza virus genetics and cell culture has enabled development of deltaFLU vaccine strains that grow to very high titers in Vero cells. The technology is applicable to production of all deltaFLU vaccine strains of influenza types A and B. Vivaldi, together with its development partner Blue Sky Vaccines, filed patent applications for this high-growth strain technology in the first quarter of 2019. The technology contributes significantly to the speed and efficiency of deltaFLU production and low overall production cost per dose of deltaFLU vaccines, and will enable Vivaldi to meet the urgent demand for hundreds of millions of doses of an effective vaccine in the event of an influenza pandemic.

NewYoy Design Agency